Related Experiment Video
Updated: Feb 11, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
Published on: May 16, 2025
Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Alberto Floris1, Matteo Piga1, Arduino Aleksander Mangoni2
1Rheumatology Unit, University Clinic and AOU of Cagliari, Monserrato, Italy.
Insights
Systemic lupus erythematosus (SLE) patients face high cardiovascular risks due to accelerated atherosclerosis. Hydroxychloroquine (HCQ) shows promise in mitigating these risks by targeting inflammation and improving cardiovascular factors.
Area of Science:
- Rheumatology
- Cardiology
- Pharmacology
Background:
- Cardiovascular (CV) morbidity and mortality pose significant challenges in managing systemic lupus erythematosus (SLE).
- Accelerated atherosclerosis is a primary driver of increased CV disease risk in SLE patients, but traditional risk factors do not fully account for this elevated risk.
- The complex interplay between SLE pathogenesis and atherosclerosis contributes to CV complications.
Purpose of the Study:
- To review the evidence supporting the role of hydroxychloroquine (HCQ) in protecting against accelerated atherosclerosis and CV events in SLE patients.
- To explore the mechanisms by which HCQ may exert beneficial CV effects in SLE.
Main Methods:
- Literature review of studies investigating HCQ's effects on CV risk in SLE patients.
- Analysis of HCQ's impact on atherosclerosis pathways, including inflammation, oxidative stress, and endothelial function.
- Examination of HCQ's influence on traditional CV risk factors like dyslipidemia and diabetes.
Main Results:
- Hydroxychloroquine (HCQ) is a foundational treatment for SLE, offering benefits in disease activity, damage prevention, and mortality.
- HCQ demonstrates potential cardioprotective effects by targeting key pathways involved in accelerated atherosclerosis, such as toll-like receptor signaling, cytokine production, immune cell activation, oxidative stress, and endothelial dysfunction.
- Evidence suggests HCQ may also improve traditional CV risk factors, including dyslipidemia and diabetes, in SLE patients.
Conclusions:
- While definitive randomized controlled trials are lacking, the reviewed evidence suggests hydroxychloroquine (HCQ) offers beneficial effects against accelerated atherosclerosis and cardiovascular events in patients with systemic lupus erythematosus (SLE).
- HCQ's multifaceted mechanisms of action support its role in cardiovascular risk reduction for SLE patients.
Abstract:
Cardiovascular (CV) morbidity and mortality are a challenge in management of patients with systemic lupus erythematosus (SLE). Higher risk of CV disease in SLE patients is mostly related to accelerated atherosclerosis. Nevertheless, high prevalence of traditional cardiovascular risk factors in SLE patients does not fully explain the increased CV risk. Despite the pathological bases of accelerated atherosclerosis are not fully understood, it is thought that this process is driven by the complex interplay between SLE and atherosclerosis pathogenesis. Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality. Furthermore, HCQ is thought to protect against accelerated atherosclerosis targeting toll-like receptor signaling, cytokine production, T-cell and monocyte activation, oxidative stress, and endothelial dysfunction. HCQ was also described to have beneficial effects on traditional CV risk factors, such as dyslipidemia and diabetes. In conclusion, despite lacking randomized controlled trials unambiguously proving the protection of HCQ against accelerated atherosclerosis and incidence of CV events in SLE patients, evidence analyzed in this review is in favor of its beneficial effect.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Accelerators
The effectiveness of calcium chloride can...
Average Acceleration
Instantaneous Acceleration
Acceleration Vectors

